{
    "clinical_study": {
        "@rank": "50311", 
        "arm_group": {
            "arm_group_label": "Everolimus", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a single-armed, open-labeled and single-centered study of everolimus in selective\n      patients with metastatic melanoma for evaluation of the efficacy and safety. The study\n      objective is to evaluate efficacy profile of everolimus.\n\n      The patients who comply with the inclusion and exclusion criteria will be enrolled. The\n      estimated recruiting duration is 18 months. Everolimus will be given in the dose of 10 mg\n      orally each day at lease 6 months unless disease progression or intolerance. The follow-up\n      is till death(at least 1 year)."
        }, 
        "brief_title": "Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study", 
        "condition": [
            "Melanoma", 
            "TOR Serine-Threonine Kinases", 
            "Neoplasm Metastasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Melanoma", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Clinical diagnosis of  metastases melanoma. Must have evidence of mutations(Kinase domain)\n        of mTOR . Must be ECOG performance status 0,1, or 2 . Must be estimated life expectancy of\n        3 months or greater. Must be age 18 years or older, male or female. Must have at least one\n        measurable site of disease as defined by at least 1 cm in greatest dimension.\n\n        Adequate organ function. Must be willingness and ability to comply with scheduled visits,\n        treatment plans, laboratory tests, and other study procedures.\n\n        Exclusion Criteria:\n\n        Prior systemic therapy for metastatic disease within 4 weeks. Second malignancy within the\n        last 5 years. Severe and/or uncontrolled medical disease. Received RAD001 or other mTOR\n        inhibitors previously . Hypersensitivity to everolimus Current treatment on another\n        clinical trial. Pregnancy or breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01960829", 
            "org_study_id": "CRAD001CCN28T"
        }, 
        "intervention": {
            "arm_group_label": "Everolimus", 
            "intervention_name": "Everolimus", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "melanoma", 
            "TOR Serine-Threonine Kinases"
        ], 
        "lastchanged_date": "October 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100142"
                }, 
                "name": "LuSi"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-armed, Open-labeled and Single-centered Phase II Trial of Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To assess the progression-free survival (PFS) after treatment with everolimus in selected patients with metastatic melanoma (with mTOR mutation).", 
            "safety_issue": "Yes", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01960829"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Beijing Cancer Hospital", 
            "investigator_full_name": "Lu Si", 
            "investigator_title": "Beijing Cancer Hospital Department of Renal Cancer and Melanoma", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "To assess the overall survival (OS) after treatment with everolimus in selected patients with metastatic melanoma (with mTOR mutation).", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "To evaluate the safety of and tolerability to everolimus in Chinese melanoma patients.", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "To evaluate the quality of life. Strategic goal: Explore and Capitalize on New Indications.", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }
        ], 
        "source": "Beijing Cancer Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Cancer Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}